Guy Jean Savoir – CEO, Carnot Laboratories
Guy Jean Savoir, CEO of family-run Mexican pharma Carnot Laboratories explains the company’s USD 150 million investment in a new facility, its plans to focus manufacturing efforts on vaccines and…
The National Institute of Psychiatry Ramón de la Fuente is a decentralized public institution part of the system of National Institutes of Health in Mexico. Founded in 1976 the functions of the Institute are: to conduct scientific research, to instruct qualified personnel to conduct these investigations, to train professionals and technicians in these fields, to treat psychiatric patients and to act as an advisor to other official and private organisms. The Institute participates in the development of health policies by coordinating with institutions at national level with both the government and civil society, by helping in the adoption of new policies in the areas of mental health and substance abuse in its role as member of the National Council against Addictions and organism in charge of mental health in the country. Since 1976 the Institute has been designated as a WHO/PAHO Collaborating Centre and been continuously re-designated every four years until 2015. The Institute possesses three research branches― neuroscience, clinical, epidemiological, and psychosocial research — an education office and an area of clinical services.
Guy Jean Savoir, CEO of family-run Mexican pharma Carnot Laboratories explains the company’s USD 150 million investment in a new facility, its plans to focus manufacturing efforts on vaccines and…
Ana Riquelme Francistain, executive director of the MedTech trade group Asociación Mexicana de Industrias Innovadoras de Dispositivos Médicos (AMID), details the trade and tax incentives that have favoured nearshoring from…
Four years ago, Daniel Del Conde left a career in multinational pharma to become the CEO of regional player Grupo Somar. He walks us through the company’s activities – private…
While the COVID-19 pandemic revealed vulnerabilities that sent many organizations looking for ways to bring supply chains closer to home, geopolitical tensions have also encouraged companies to avoid dependence on…
In a move to address medicine shortages Mexico’s outgoing president Andrés Manuel López Obrador last year launched a Super Pharmacy, or “Megafarmacia del Bienestar,” dubbed the largest medicine stockpile n…
The latest stories from Mexican pharma and healthcare, including Sanfer’s purchase of Colombia-based manufacturer Vitalis; Organon Mexico’s new business; the FDA’s warning to Glicerinas Industriales, and a look at the issues,…
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.…
Latin America’s patient organisations are today playing a more important role than ever before in developing solutions to the continent’s most pressing healthcare challenges. Given the healthcare gaps that persist,…
Back in Latin America after several years in the US and Europe, Teva LatAm Head and Mexico GM Rodrigo Fernandez explains how the affiliate has adapted its strategy across the…
Mexico, with the second largest pharmaceutical market in Latin America, has a number of strong local pharma industry players. These companies, no longer focused solely on the domestic market, are…
María del Socorro España Lomelí, the executive director of Mexico’s National Association of Manufacturers of Medicines (ANAFAM), speaks to PharmaBoardroom about ANAFAM’s evolving relationship with the Mexican government and the…
See our Cookie Privacy Policy Here
